PeptideHelper.org
Your evidence-based peptide reference
Research reference only. Not medical advice. Most compounds are not FDA-approved. Consult a qualified clinician before any human use.

Other & Emerging

VIP

Vasoactive Intestinal Peptide; Aviptadil

Classification: Neuropeptide hormone; multi-organ regulator

Mechanism: VPAC1/VPAC2 receptor agonist; vasodilation; anti-inflammatory; surfactant production

Benefits: Vasodilation; anti-inflammatory; gut function; ARDS (COVID trials); CIRS research

Evidence tier: Phase 3 (Aviptadil) / Off-Label · Availability: Investigational / Compounded

Primary sources

  1. Youssef JG et al. Use of IV vasoactive intestinal peptide (aviptadil) in patients with critical COVID-19 respiratory failure — 60-day randomized controlled trial. Crit Care Med 2022. PMID 36044317
  2. Langer I et al. Signal transduction by VIP and PACAP receptors. Biomedicines 2022. PMID 35203615

Loading interactive view…